Evidence map›Paper›PMID 36382553›Full record

ArticleMolecular nutrition & food research2023

Butyrate Attenuates Hepatic Steatosis Induced by a High-Fat and Fiber-Deficient Diet via the Hepatic GPR41/43-CaMKII/HDAC1-CREB Pathway.

Mingxuan Zheng, Xiaoying Yang, Qingyuan Wu, Yuying Gong, Ning Pang, Xing Ge, Nathan Nagaratnam, Pengfei Jiang, Menglu Zhou, Tao Hu and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular nutrition & food research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Synergistic effects ofFrontiers in nutrition · 2026
    Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Mingxuan ZhengJiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogen Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, P. R. China.ORCID 0000-0001-9406-2437
Xiaoying YangJiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogen Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, P. R. China.ORCID 0000-0001-8382-9719
Qingyuan WuJiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogen Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, P. R. China.
Yuying GongJiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogen Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, P. R. China.
Ning PangTianjin Third Central Hospital, Tianjin, 300170, P. R. China.
Xing GeJiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogen Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, P. R. China.
Nathan NagaratnamIllawarra Health and Medical Research Institute, (IHMRI) and School of Medicine, University of Wollongong, Wollongong, NSW, 2522, Australia.
Pengfei JiangJiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogen Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, P. R. China.
Menglu ZhouJiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogen Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, P. R. China.
Tao HuJiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogen Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, P. R. China.
Hui HuaJiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogen Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, P. R. China.
Kuiyang ZhengJiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogen Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, P. R. China.
Xu-Feng HuangIllawarra Health and Medical Research Institute, (IHMRI) and School of Medicine, University of Wollongong, Wollongong, NSW, 2522, Australia.
Yinghua YuJiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogen Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, P. R. China.ORCID 0000-0003-2508-7512
Xuzhou Medical College · CNUniversity of Wollongong · AUTianjin Third Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

scopeHepatic steatosis is a major health issue that can be attenuated by a healthy diet. This study investigates the effects and molecular mechanisms of butyrate, a dietary fiber metabolite of gut microbiota, on lipid metabolism in hepatocytes. METHODS AND

resultsThis study examines the effects of butyrate (0-8 mM) on lipid metabolism in primary hepatocytes. The results show that butyrate (2 mM) consistently inhibits lipogenic genes and activates lipid oxidation-related gene expression in hepatocytes. Furthermore, butyrate modulates lipid metabolism genes, reduces fat droplet accumulation, and activates the calcium/calmodulin-dependent protein kinase II (CaMKII)/histone deacetylase 1 (HDAC1)-cyclic adenosine monophosphate response element binding protein (CREB) signaling pathway in the primary hepatocytes and liver of wild-type (WT) mice, but not in G-protein-coupled receptor 41 (GPR41) knockout and 43 (GPR43) knockout mice. This suggests that butyrate regulated hepatic lipid metabolism requires GPR41 and GPR43. Finally, the study finds that dietary butyrate supplementation (5%) ameliorates hepatic steatosis and abnormal lipid metabolism in the liver of mice fed a high-fat and fiber-deficient diet for 15 weeks.

conclusionThis work reveals that butyrate improves hepatic lipid metabolism through the GPR41/43-CaMKII/HDAC1-CREB pathway, providing support for consideration of butyrate as a dietary supplement to prevent the progression of NAFLD induced by the Western-style diet.

Indexed as

Calcium-Calmodulin-Dependent Protein Kinase Type 2Non-alcoholic Fatty Liver DiseaseAnimalsButyratesCyclic AMP Response Element-Binding ProteinDietDiet, High-FatHistone Deacetylase 1Lipid MetabolismLiverMiceMice, Inbred C57BLReceptors, G-Protein-CoupledButyratesCalcium-Calmodulin-Dependent Protein Kinase Type 2Creb1 protein, mouseCyclic AMP Response Element-Binding ProteinFfar2 protein, mouseGpcr41 protein, mouseHdac1 protein, mouseHistone Deacetylase 1Receptors, G-Protein-CoupledbutyrateCaMKIICREBGPR41GPR43HDAC1NAFLD

Identifiers

PMID36382553
PMCPMC10078002
OpenAlexW4309166716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.